High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay

Indian J Exp Biol. 2009 Jun;47(6):475-9.

Abstract

A simple colorimetric beta-lactamase assay for quantifying Leishmania amastigotes in macrophages grown in microtiter plates has been reported. The beta-lactamase gene was integrated into the rRNA region of the genome, thereby allowing for high-level stable expression of the enzyme. Both visceral leishmaniasis (VL) and post-kala azar dermal leishmaniasis (PKDL) isolates were transfected with beta-Lactamase gene. These beta-lactamase-expressing promastigotes were used for infecting intracellular J774A.1 macrophages in vitro. Quantification was done by a colorimetric readout with CENTA beta-lactamase as substrate and with an optical density plate reader. The assay was carried out in 96-well plates. Results obtained demonstrate that this methodology could be a valuable high-throughput screening assay for checking efficacy of anti-leishmanial drugs in the clinical isolates.

Publication types

  • Evaluation Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiprotozoal Agents / pharmacology
  • Antiprotozoal Agents / therapeutic use
  • Biological Assay / methods*
  • Genes, Reporter
  • Humans
  • Leishmania donovani / cytology
  • Leishmania donovani / drug effects
  • Leishmania donovani / metabolism*
  • Leishmaniasis, Cutaneous / drug therapy
  • Leishmaniasis, Visceral / drug therapy
  • beta-Lactamases / genetics
  • beta-Lactamases / metabolism*

Substances

  • Antiprotozoal Agents
  • beta-Lactamases